The Clinical Study Of The Treatment Of The Ct-guided Percutaneous Radiofrequency Ablation In Lung Cancer

Objective:. To evaluate the feasibility, safety, median survival time and the complete rate of the target focus with the treatment of the CT-guided percutaneous radiofrequency ablation in lung cancer.Materials and methods:The study population included 73 patients with non-small cell lung cancer and lung metastatic cancer, who could not tolerate or suitable for the operation, chemotherapy or radiation theray because of their old ages, dysfunction of heart or lung, or worse status. These patients assigned to receive the CT-guided percuatneous radiofrequency ablation operations. The efficiency and complications were evaluated through the postoperational CT examination. The patients were followed every 3 months for 2 years. The response rate and median survival time were analyzed, and the overall survival rate and cancer-related survival rate were analyzed with the Kaplan-Meier method.Results:All the 73 patients received 78 radiaofrequency ablation operations, which were all completed successfully. No treatment-realted death happened. The complications included pneumothorax 9 cases, pain 15 cases, fever 13 cases, pulmonary bleeding 5 cases, pleural effusion 1 case. The average hospitalization was 3 days (2—12 days). After 1 year follow-up, the complete response were observed in 57 patients (86%), the partial response in 9 patients (14%). The median survival time in non-small cell lung cancers and lung metastatic cancers was 28.33 and 24 months, respectively. Till the follow-up was finished,51 deaths happened, including 36 patients with non-small cell lung cancer and 15 patients with lung metastatic cancer. In the patients with non-small cell lung cancer, the death reasons included heart failure 2 cases, myocardial infarction 1 case, brain infarction 1 case and respiratory failure 2 cases. The 1-year and 2-year overall survival time in non-small cell lung cancers were 93% and 56%, respectively; while in lung metastatic cancers,94% and 61%, respectively. But the 1-year and 2-year overall survival time in the patients with I stage non-small cell lung cancers achieved 100% and 82%(11 patients) impressively. Conclusion:The radiofrequency ablation operation is a noveled micro-injuried technique for the lung cancer, with the advantages of safety, less injury, less complications, convenient operation. The patients could recover soon after that operation, which is an appropriate treatment to the patients with non-small cell lung cancers and lung metastatic cancers, who could not tolerate or suitable for the operation, chemotherapy or radiationtheray because of their old ages, dysfunction of heart or lung, or worse status. It is also an alternative palliative strategy for the lung metastatic cancer. This operatin achieved an significant short-term efficiency, but the long-term result need further observation.